Pfizer gets into in vivo CAR-T through licensing deal with Chinese biotech
Pfizer is set to pay $330 million upfront to Starna Therapeutics to take exclusive rights to three pre-IND in vivo CAR-T assets in autoimmune disease …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







